sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
This article was originally published in The Pink Sheet Daily
Executive Summary
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.